Amgen: Neoplasms trials

The registry lists 55 Neoplasms studies with Amgen as lead sponsor. 2 are open to participants now and 14 have results posted.

Phase 1 26Phase 2 18Phase 3 12No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationRecruitingNCT06252649Phase 3
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingNCT05920356Phase 3
• Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of TreatmentActive, not recruitingNCT06502977Phase 2Results posted
• Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid TumorsCompletedNCT04727554Phase 1Results posted
• FPT155 in Patients With Advanced Solid TumorsTerminatedNCT04074759Phase 1Results posted
• Study of Talimogene Laherparepvec In Children With Advanced Non CNS TumorsCompletedNCT02756845Phase 1Results posted
• Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT02393859Phase 3Results posted
• Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic ImpairmentCompletedNCT01949545Phase 1Results posted
• Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple MyelomaCompletedNCT01345019Phase 3Results posted
• Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)CompletedNCT01327612Phase 2Results posted
• Darbepoetin Alfa and Anemia of CancerTerminatedNCT00989092Phase 2Results posted
• Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumCompletedNCT00896454Phase 2Results posted
• Study of Denosumab in Subjects With Giant Cell Tumor of BoneCompletedNCT00680992Phase 2Results posted
• Panitumumab in Children With Solid TumorsCompletedNCT00658658Phase 1Results posted
• Darbepoetin Alfa With or Without Intravenous (IV) IronCompletedNCT00401544Phase 2Results posted
• Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) BisphosphonatesCompletedNCT00104650Phase 2Results posted
• Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)Active, not recruitingNCT06691984Phase 3
• A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)Active, not recruitingNCT06593522Phase 2
• A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)Active, not recruitingNCT06360354Phase 1
• Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).Active, not recruitingNCT06333951Phase 1
• A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid TumorsCompletedNCT05975073Phase 1/2
• Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)Active, not recruitingNCT03319940Phase 1
• A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT03287908Phase 1
• Post-Marketing Surveillance Study of OTEZLACompletedNCT03284879
• Safety Study of AMG 228 to Treat Solid TumorsTerminatedNCT02437916Phase 1
• A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced MalignanciesTerminatedNCT02244112Phase 1
• Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid TumorsCompletedNCT01386866Phase 1
• AMG 319 Lymphoid Malignancy FIHCompletedNCT01300026Phase 1
• A Study of AMG 337 in Subjects With Advanced Solid TumorsCompletedNCT01253707Phase 1
• A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid TumorsCompletedNCT01235416Phase 1
• A Phase 1 Dose Escalation Study of AMG 780 in Adult Subjects With Advanced Solid TumorsTerminatedNCT01137552Phase 1
• Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid TumorsCompletedNCT01129349Phase 1
• A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid TumorsCompletedNCT00858377Phase 1
• A Phase 1 Study of AMG 208 in Subjects With Advanced Solid TumorsCompletedNCT00813384Phase 1
• AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CRCompletedNCT00770536Phase 1
• Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin AlfaCompletedNCT00540696Phase 2
• Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid TumorsCompletedNCT00448786Phase 1
• Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid MalignanciesCompletedNCT00239239Phase 2
• Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.CompletedNCT00148421Phase 3
• Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to ChemotherapyCompletedNCT00144131Phase 2
• AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid MalignanciesCompletedNCT00135317Phase 3
• Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to ChemotherapyCompletedNCT00121030Phase 2
• Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving ChemotherapyCompletedNCT00120705Phase 2
• A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle ChemotherapyTerminatedNCT00119600Phase 1/2
• A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle ChemotherapyCompletedNCT00118638Phase 3
• A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid MalignancyCompletedNCT00117624Phase 3
• Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle ChemotherapyCompletedNCT00111462Phase 2
• Treatment for Patients With Non-Myeloid Malignancies Receiving ChemotherapyCompletedNCT00111137Phase 3
• Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle ChemotherapyCompletedNCT00110955Phase 3
• Study Evaluating AMG 386 in Adult Patients With Advanced Solid TumorsCompletedNCT00102830Phase 1
• Study Evaluating AMG 706 in Subjects With Advanced Solid TumorsCompletedNCT00093873Phase 1
• Two Dose Schedules of Panitumumab in Subjects With Advanced Solid TumorsCompletedNCT00091806Phase 1
• Anemia in Patients With a Non-Myeloid MalignancyCompletedNCT00038064Phase 3
• Chemotherapy Related Anemia in Patients With Non-Myeloid MalignanciesCompletedNCT00036023Phase 2
• Chemotherapy Related AnemiaCompletedNCT00035607Phase 2